Steve Byrne

Potash Corporation of Saskatchewan (USA) (NYSE: POT) shares have declined 46.43 percent year-to-date, trading almost at their 52-week low on December 4. Steve Byrne of Bank of America Merrill Lynch has reinitiated coverage of the company with an Underperform rating and price target of $20...

Bank of America upgraded Sarepta Therapeutics Inc (NASDAQ: SRPT) from Neutral to Buy on Tuesday and raised its price target from $19 to $21. Analyst Steve Byrne based the upgrade on the “increased conviction” that the company’s eleplirsen drug for Duchenne muscular dystrophy (...

In a report published Thursday, Bank of America analyst Steve Byrne reiterated an Underperform rating on BioCryst Pharmaceuticals (NASDAQ: BCRX), but lowered the price target from $9.00 to $8.00. In the report, Bank of America noted, “We recently conducted a survey of 20 EU physicians treating HAE...

Bank of America on Monday published a Q3 2014 earnings preview for small- to mid-cap biotech companies. Analyst Steve Byrne noted that valuations are more attractive after the recent pull-back. Below are highlights from the report with the firm’s current ratings and price targets....

In a report published Wednesday, Bank of America analyst Steve Byrne reiterated a Buy rating and $105.00 price target on Pacira Pharmaceuticals (NASDAQ: PCRX). In the report, Bank of America noted, “PCRX CFO Jim Scibetta led a tour yesterday of the company's San Diego-based manufacturing facility,...

In a report published Tuesday, Bank of America analyst Steve Byrne downgraded the rating on Seattle Genetics, Inc. (NASDAQ: SGEN) from Neutral to Underperform, and lowered the price target from $40.00 to $34.00. In the report, Bank of America noted, “Following PTCL data from ESMO and post-...

In a report published Friday, Bank of America analyst Steve Byrne reiterated a Buy rating on Vital Therapies (NASDAQ: VTL), and raised the price target from $20.00 to $40.00. In the report, Bank of America noted, “Following the recent update on the enrollment rate and patient characteristics in the...

In a report published Thursday, Bank of America analyst Steve Byrne downgraded the rating on Theravance (NASDAQ: THRX) from Buy to Neutral, and lowered the price target from $34.00 to $31.00. In the report, Bank of America noted, “Following comments from GSK on its 2Q14 results call on continued...

In a report published Thursday, Bank of America analyst Steve Byrne reiterated a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised the price target from $86.00 to $104.00. In the report, Bank of America noted, “We are raising our PO to $104 (from $86) based on positive results from...

In a report published Wednesday, Bank of America analyst Steve Byrne reiterated an Underperform rating on BioCryst Pharmaceuticals (NASDAQ: BCRX), and raised the price target from $8.00 to $9.00. In the report, Bank of America noted, “As we had expected, BCRX announced positive proof of concept...

In a report published Tuesday, Bank of America analyst Steve Byrne upgraded the rating on Seattle Genetics (NASDAQ: SGEN) from Underperform to Neutral, but lowered the price target from $46.00 to $40.00. In the report, Bank of America noted, “We rate SGEN shares Neutral. While we believe...

In a report published Thursday, Bank of America analyst Steve Byrne reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI), and raised the price target from $40.00 to $48.00. In the report, Bank of America noted, “We are raising our PO to $48 (from $40) based on the potential for use in...

In a report published Wednesday, Bank of America analyst Steve Byrne reinstated coverage on Incyte (NASDAQ: INCY) with a Buy rating and $84.00 price target. In the report, Bank of America noted, “We are reinstating coverage of Incyte (INCY) with a Buy rating and $84 PO. The company's single...